{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:46:58Z","timestamp":1787507218505,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The coronavirus disease 2019 (COVID-19) global pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, our understanding of SARS-CoV-2-induced inflammation in alveolar epithelial cells remains very limited. The contributions of intracellular insulin-like growth factor binding protein-2 (IGFBP2) to SARS-CoV-2 pathogenesis are also unclear. In this study, we have uncovered a critical role for IGFBP2, specifically in alveolar epithelial\u00a0type\u00a02 cells (AEC2), in the immunopathogenesis of COVID-19. Using bulk RNA sequencing, we show that\n                    <jats:italic>IGFBP2<\/jats:italic>\n                    mRNA expression is significantly downregulated in primary AEC2 cells isolated from fibrotic lung regions from patients with COVID-19-acute respiratory distress syndrome (ARDS) compared to those with idiopathic pulmonary fibrosis (IPF) alone or IPF with a history of COVID-19. Using multicolor immunohistochemistry, we demonstrated that IGFBP2 and its selective ligands IGF1 and IGF2 were significantly reduced in AEC2 cells from patients with COVID-ARDS, IPF alone, or IPF with COVID history than in those from age-matched donor controls. Further, we demonstrated that lentiviral expression of\n                    <jats:italic>Igfbp2<\/jats:italic>\n                    significantly reduced mRNA expression of proinflammatory cytokines\u2014Tnf-\u03b1, Il1\u03b2, Il6, Stat3, Stat6 and chemokine receptors\u2014Ccr2 and Ccr5\u2014in mouse lung epithelial cells challenged with SARS-CoV-2 spike protein injury (S2; 500\u00a0ng\/mL). Finally, we demonstrated higher levels of cytokines\u2014TNF-\u03b1; IL-6 and chemokine receptor\u2014CCR5 in AEC2 cells from COVID-ARDS patients compared to the IPF alone and the IPF with COVID history patients. Altogether, these data suggest that anti-inflammatory properties of IGFBP2 in AEC2 cells and its localized delivery may serve as potential therapeutic strategy for patients with COVID-19.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12931-025-03187-9","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T07:34:08Z","timestamp":1742628848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alveolar epithelial\u00a0type 2\u00a0cell specific loss of IGFBP2 activates inflammation in COVID-19"],"prefix":"10.1186","volume":"26","author":[{"given":"Valentina","family":"Pujadas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiahsuan","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra V.","family":"Sankpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Buhrmaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Arjuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Walia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Eickelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross M.","family":"Bremner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalachallour","family":"Mohanakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angara","family":"Sureshbabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"3187_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001143","volume":"19","author":"NG Ravindra","year":"2021","unstructured":"Ravindra NG, Alfajaro MM, Gasque V, Huston NC, Wan H, Szigeti-Buck K, Yasumoto Y, Greaney AM, Habet V, Chow RD, et al. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biol. 2021;19: e3001143.","journal-title":"PLoS Biol"},{"key":"3187_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, Kato T, Lee RE, Yount BL, Mascenik TM, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429-446.e414.","journal-title":"Cell"},{"key":"3187_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"F Scialo","year":"2020","unstructured":"Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G, Bianco A. ACE2: the major cell entry receptor for SARS-CoV-2. Lung. 2020;198:867\u201377.","journal-title":"Lung"},{"key":"3187_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","volume":"15","author":"S Tian","year":"2020","unstructured":"Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (Covid-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700\u20134.","journal-title":"J Thorac Oncol"},{"key":"3187_CR5","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3201\/eid2609.202095","volume":"26","author":"RB Martines","year":"2020","unstructured":"Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, Goldsmith CS, Silva-Flannery L, Seixas JN, Reagan-Steiner S, et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease United States. Emerg Infect Dis. 2020;26:2005\u201315.","journal-title":"Emerg Infect Dis"},{"key":"3187_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153195","volume":"216","author":"G Mansueto","year":"2020","unstructured":"Mansueto G. COVID-19: Brief check through the pathologist\u2019s eye (autopsy archive). Pathol Res Pract. 2020;216: 153195.","journal-title":"Pathol Res Pract"},{"key":"3187_CR7","volume":"25","author":"A Adegunsoye","year":"2023","unstructured":"Adegunsoye A, Baccile R, Best TJ, Zaksas V, Zhang H, Karnik R, Patel BK, Solomonides AE, Parker WF, Solway J. Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States. Lancet Reg Health Am. 2023;25: 100566.","journal-title":"Lancet Reg Health Am"},{"key":"3187_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/atm.atm_7_23","volume":"18","author":"NN Alrajhi","year":"2023","unstructured":"Alrajhi NN. Post-COVID-19 pulmonary fibrosis: an ongoing concern. Ann Thorac Med. 2023;18:173\u201381.","journal-title":"Ann Thorac Med"},{"key":"3187_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140289","author":"JG Wilson","year":"2020","unstructured":"Wilson JG, Simpson LJ, Ferreira AM, Rustagi A, Roque J, Asuni A, Ranganath T, Grant PM, Subramanian A, Rosenberg-Hasson Y, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.140289.","journal-title":"JCI Insight"},{"key":"3187_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","volume":"19","author":"S Montazersaheb","year":"2022","unstructured":"Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, Farahzadi R, Ghasemnejad T. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19:92.","journal-title":"Virol J"},{"key":"3187_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"3187_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","volume":"26","author":"W Sungnak","year":"2020","unstructured":"Sungnak W, Huang N, B\u00e9cavin C, Berg M, Queen R, Litvinukova M, Talavera-L\u00f3pez C, Maatz H, Reichart D, Sampaziotis F, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681\u20137.","journal-title":"Nat Med"},{"key":"3187_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.202001-0179LE","volume":"202","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:756\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3187_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.stem.2020.09.013","volume":"27","author":"J Huang","year":"2020","unstructured":"Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell. 2020;27:962-973.e967.","journal-title":"Cell Stem Cell"},{"key":"3187_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.stem.2020.10.005","volume":"27","author":"H Katsura","year":"2020","unstructured":"Katsura H, Sontake V, Tata A, Kobayashi Y, Edwards CE, Heaton BE, Konkimalla A, Asakura T, Mikami Y, Fritch EJ, et al. Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-mediated interferon responses and pneumocyte dysfunction. Cell Stem Cell. 2020;27:890-904.e898.","journal-title":"Cell Stem Cell"},{"key":"3187_CR16","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1016\/j.cell.2021.11.033","volume":"184","author":"D Wendisch","year":"2021","unstructured":"Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184:6243-6261.e6227.","journal-title":"Cell"},{"key":"3187_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cytogfr.2014.12.001","volume":"26","author":"VC Russo","year":"2015","unstructured":"Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA. IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 2015;26:329\u201346.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3187_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100945","volume":"4","author":"C Chin","year":"2023","unstructured":"Chin C, Ravichandran R, Sanborn K, Fleming T, Wheatcroft SB, Kearney MT, Tokman S, Walia R, Smith MA, Flint DJ, et al. Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis. Cell Rep Med. 2023;4: 100945.","journal-title":"Cell Rep Med"},{"key":"3187_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-023-01368-w","volume":"8","author":"S Liang","year":"2023","unstructured":"Liang S, Bao C, Yang Z, Liu S, Sun Y, Cao W, Wang T, Schwantes-An TH, Choy JS, Naidu S, et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. Signal Transduct Target Ther. 2023;8:108.","journal-title":"Signal Transduct Target Ther"},{"key":"3187_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463\u20139.","journal-title":"Nature"},{"key":"3187_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2020.102125","volume":"50","author":"S Xiaojie","year":"2020","unstructured":"Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020;50: 102125.","journal-title":"Stem Cell Res"},{"key":"3187_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"3187_CR23","doi-asserted-by":"publisher","first-page":"1033674","DOI":"10.3389\/fphar.2022.1033674","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Tang G, Liu Y, Zhang L, Chen B, Han Y, Fu Z, Wang L, Hu G, Ma Q, et al. The role of IL-6 in coronavirus, especially in COVID-19. Front Pharmacol. 2022;13:1033674.","journal-title":"Front Pharmacol"},{"key":"3187_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076142","author":"Z Mohd Zawawi","year":"2023","unstructured":"Mohd Zawawi Z, Kalyanasundram J, Mohd Zain R, Thayan R, Basri DF, Yap WB. Prospective roles of tumor necrosis factor-alpha (TNF-\u03b1) in COVID-19: prognosis, therapeutic and management. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076142.","journal-title":"Int J Mol Sci"},{"key":"3187_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","volume":"103","author":"BK Patterson","year":"2021","unstructured":"Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021;103:25\u201332.","journal-title":"Int J Infect Dis"},{"key":"3187_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.annepidem.2009.11.005","volume":"20","author":"N Mehrotra","year":"2010","unstructured":"Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB, Meibohm B. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol. 2010;20:223\u201332.","journal-title":"Ann Epidemiol"},{"key":"3187_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1374","volume":"11","author":"LD Samson","year":"2022","unstructured":"Samson LD, Buisman AM, Ferreira JA, Picavet HSJ, Verschuren WMM, Boots AM, Engelfriet P. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. Clin Transl Immunology. 2022;11: e1374.","journal-title":"Clin Transl Immunology"},{"key":"3187_CR28","unstructured":"COVID - Coronavirus Statistics - Worldometer. 2024."},{"key":"3187_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742941","volume":"12","author":"LY Tan","year":"2021","unstructured":"Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Hyperinflammatory immune response and COVID-19: a double edged sword. Front Immunol. 2021;12: 742941.","journal-title":"Front Immunol"},{"key":"3187_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2021.09.001","volume":"241","author":"JE Michalski","year":"2022","unstructured":"Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res. 2022;241:13\u201324.","journal-title":"Transl Res"},{"key":"3187_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/16000617.0194-2021","volume":"30","author":"RJ Mylvaganam","year":"2021","unstructured":"Mylvaganam RJ, Bailey JI, Sznajder JI, Sala MA. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev. 2021;30:162.","journal-title":"Eur Respir Rev"},{"key":"3187_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s41030-023-00226-y","volume":"9","author":"S Duong-Quy","year":"2023","unstructured":"Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q, Nguyen-Nhu V. Post-COVID-19 pulmonary fibrosis: facts-challenges and futures: a narrative review. Pulm Ther. 2023;9:295\u2013307.","journal-title":"Pulm Ther"},{"key":"3187_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055084","volume":"8","author":"L Mohanraj","year":"2013","unstructured":"Mohanraj L, Kim HS, Li W, Cai Q, Kim KE, Shin HJ, Lee YJ, Lee WJ, Kim JH, Oh Y. IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis. PLoS ONE. 2013;8: e55084.","journal-title":"PLoS ONE"},{"key":"3187_CR34","first-page":"796","volume":"19","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Jiang Y, Toutounchian JJ, Soderland C, Yates CR, Steinle JJ. Insulin-like growth factor binding protein-3 inhibits monocyte adhesion to retinal endothelial cells in high glucose conditions. Mol Vis. 2013;19:796\u2013803.","journal-title":"Mol Vis"},{"issue":"2","key":"3187_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/antiox11020275","volume":"11","author":"L Longhitano","year":"2022","unstructured":"Longhitano L, Forte S, Orlando L, Grasso S, Barbato A, Vicario N, Parenti R, Fontana P, Amorini AM, Lazzarino G, et al. The crosstalk between GPR81\/IGFBP6 promotes breast cancer progression by modulating lactate metabolism and oxidative stress. Antioxidants (Basel). 2022;11(2):275.","journal-title":"Antioxidants (Basel)"},{"key":"3187_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355\u201362.","journal-title":"Nat Rev Immunol"},{"key":"3187_CR37","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1172\/JCI145301","volume":"130","author":"JE Weatherhead","year":"2020","unstructured":"Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130:6194\u20137.","journal-title":"J Clin Invest"},{"key":"3187_CR38","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","volume":"54","author":"L Bergamaschi","year":"2021","unstructured":"Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, Ruffieux H, De Sa A, Huhn O, Morgan MD, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257-1275.e1258.","journal-title":"Immunity"},{"key":"3187_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260623","volume":"16","author":"HS Ozger","year":"2021","unstructured":"Ozger HS, Karakus R, Kuscu EN, Bagriacik UE, Oruklu N, Yaman M, Turkoglu M, Erbas G, Atak AY, Senol E. Serial measurement of cytokines strongly predict COVID-19 outcome. PLoS ONE. 2021;16: e0260623.","journal-title":"PLoS ONE"},{"key":"3187_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279935","volume":"18","author":"A Jamoussi","year":"2023","unstructured":"Jamoussi A, Messaoud L, Jarraya F, Rachdi E, Ben Mrad N, Yaalaoui S, Besbes M, Ayed S, Ben Khelil J. Interleukin6 prediction of mortality in critically ill COVID19 patients: a prospective observational cohort study. PLoS ONE. 2023;18: e0279935.","journal-title":"PLoS ONE"},{"key":"3187_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032864","volume":"7","author":"G Kothandan","year":"2012","unstructured":"Kothandan G, Gadhe CG, Cho SJ. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study. PLoS ONE. 2012;7: e32864.","journal-title":"PLoS ONE"},{"key":"3187_CR42","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.934725","author":"N Star\u010devi\u0107 \u010cizmarevi\u0107","year":"2021","unstructured":"Star\u010devi\u0107 \u010cizmarevi\u0107 N, Kapovi\u0107 M, Ron\u010devi\u0107 D, Risti\u0107 S. Could the CCR5-\u039432 mutation be protective in SARS-CoV-2 infection? Physiol Res. 2021. https:\/\/doi.org\/10.33549\/physiolres.934725.","journal-title":"Physiol Res"},{"key":"3187_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/138945011701151217110917","volume":"17","author":"DA Covino","year":"2016","unstructured":"Covino DA, Sabbatucci M, Fantuzzi L. The CCL2\/CCR2 axis in the pathogenesis of hiv-1 infection: a new cellular target for therapy? Curr Drug Targets. 2016;17:76\u2013110.","journal-title":"Curr Drug Targets"},{"key":"3187_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cytogfr.2020.08.004","volume":"57","author":"A Rani","year":"2021","unstructured":"Rani A, Chin C, Bremner R, Mohanakumar T, Angara S. Targeting chromatin dysregulation in organ fibrosis. Cytokine Growth Factor Rev. 2021;57:64\u201372.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3187_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-021-00646-9","volume":"6","author":"X Zhu","year":"2021","unstructured":"Zhu X, Chen Z, Shen W, Huang G, Sedivy JM, Wang H, Ju Z. Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention. Signal Transduct Target Ther. 2021;6:245.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03187-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T18:13:24Z","timestamp":1742926404000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03187-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3187"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03187-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For human lung tissue procurement, fibrotic lung tissues were acquired from patients undergoing lung transplantation at St. Joseph\u2019s Hospital and Medical Center after approval by the Institutional Review Board. All human lung tissues were de-identified and the study protocol was approved by the local ethics committee for medical research purposes. All enrolled patients have provided informed consent (IRB# PHX-21-500-138-73-18). Age-matched donor (healthy) control lung tissues were obtained from the National Disease Research Interchange (NDRI, Philadelphia, PA). No animals were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}